Recent research examine Namilumab, a engineered antibody directed CSF2 (Colony Stimulating Factor 2), also known as GM-CSF. This innovative therapeutic approach is showing promise in managing conditions driven by CSF2's pathological role. Namilumab works … Read More

Rosmantuzumab: A Deep Dive into OMP-131R10 Rosmantuzumab, originally known as OMP-131R10, constitutes a novel monoclonal antibody designed to inhibit granulocyte-macrophage colony-stimulating GM-CSF. Its mode of action requires selectively interacting to GM-CSF, reducing its engagement … Read More